Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

pharmaceutical-business-reviewAugust 11, 2020

Tag: Daiichi Sankyo , AstraZeneca , patritumab deruxtecan , NSCLC , Tagrisso

PharmaSources Customer Service